1. Мазо Е.Б., Гамидов С.И., Иремашвили В.В., Гасанов Р.В. Патогенез эректильной дисфункции при метаболическом синдроме. Вестн. РАМН. 2008; 2: 21–6.
2. Svartberg J. Epidemiology: testosterone and the metabolic syndrome. Int J Impot Res 2007; 19: 124–8.
3. Malkin CJ, Pugh PJ, West JN et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006; 27: 57–64.
4. Khaw KT, Dowsett M, Folkerd E et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007; 116: 2694–701.
5. Muller M, Grobbee DE, den Tonkelaar I et al. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005; 90: 2618–23.
6. Tomar R, Dhindsa S, Chaudhuri A et al. Contrasting testosterone concentrations in type 1 and type 2 diabetes. Diabetes Care 2006; 29: 1120–2.
7. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899–906.
8. Pitteloud N, Hardin M, Dwyer AA et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005; 90: 2636–41.
9. Wake DJ, Strand M, Rask E et al. Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clin Endocrinol (Oxf) 2007; 66: 440–6.
10. Dandona P, Dhindsa S, Chaudhuri A et al. Hypogonadotrophic hypogonadism in type 2 diabetes, obesity and the metabolic syndrome. Curr Mol Med 2008; 8: 816–28.
11. Van Pottelbergh I, Braeckman L, De Bacquer D et al. Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis 2003; 166: 95–102.
12. Svartberg J, von Muhlen D, Schirmer H et al. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso Study. Eur J Endocrinol 2004; 150: 65–71.
13. Lu YL, Kuang L, Zhu H et al. Changes in aortic endothelium ultrastructure in male rats following castration, replacement with testosterone and administration of 5alpha-reductase inhibitor. Asian J Androl 2007; 9: 843–7.
14. Foresta C, Zuccarello D, De Toni L et al. Androgens stimulate endothelial progenitor cells through an androgen receptor-mediated pathway. Clin Endocrinol (Oxf) 2008; 68: 284–9.
15. Bowles DK, Maddali KK, Dhulipala VC, Korzick DH. PKCdelta mediates anti-proliferative, pro-apoptic effects of testosterone on coronary smooth muscle. Am J Physiol Cell Physiol 2007; 293: C805–13.
16. Harle L, Basaria S, Dobs AS. Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin Pharmacother 2005; 6: 1751–9.
17. Morgentaler A, Lipshultz LI, Bennett R et al. Testosterone therapy in men with untreated prostate cancer. J Urol 2011; 185: 1256–61.
18. Snyder PJ. Might testosterone actually reduce mortality? J Clin Endocrinol Metab 2008; 93: 32–3.
19. Zhonghua Yi Xue Za Zhi 2008; 88 (36): 2550–2.
20. Zitzmann M et al. Endo 2005. Abstract Book: 306.
21. Guler N, Batyraliev T, Dulger H et al. The effects of short term (3 weeks) testosterone treatment on serum inflammatory markers in men undergoing coronary artery stenting. Int J Cardiol 2006; 109: 339–43.
22. Foresta C, Caretta N, Lana A et al. Reduced number of circulating endothelial progenitor cells in hypogonadal men. J Clin Endocrinol Metab 2006; 91: 4599–602.
23.Wynne FL, Khalil RA. J Endocrinol Invest 2003; 26: 181–6.
24. English KM et al. Circulation 102, 2000; p. 1906–11.

С.И.Гамидов1,2, Р.И.Овчинников1, А.Ю.Попова1, К.И.Крамарева2, П.Д.Никитин2

1. ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава РФ;
2. Урологическая клиника ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава РФ